Stock Events

Stock Events

Tonix Pharmaceuticals 

$12.73
580
+$0.07+0.55% Wednesday 20:00
+$0.13+1.01%Wednesday 23:55After hours

Statistics

Day High
13.16
Day Low
12.63
52W High
39.45
52W Low
9.4
Volume
595,234
Avg. Volume
526,403
Mkt Cap
218.33M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-18.5
-13.15
-7.79
-2.44
Expected EPS
-2.48
Actual EPS
N/A

Financials

-946.22%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
13.11MRevenue
-124.02MNet Income

Analyst Ratings

26.00Average Price Target
The highest estimate is 26.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNXP. It's not an investment recommendation.
Apple
68
AAPL
NVIDIA
68
NVDA
Microsoft
58
MSFT
Tesla
57
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.33B
Novavax is involved in the development of vaccines and therapeutics for infectious diseases, directly competing with Tonix's focus on immunology and infectious diseases.
Moderna
MRNA
Mkt Cap25.28B
Moderna is a leader in mRNA technology for vaccines, competing in the infectious disease space where Tonix Pharmaceuticals also operates.
BioNTech
BNTX
Mkt Cap23.38B
BioNTech competes in the development of vaccines and immunotherapies, overlapping with Tonix's focus areas.
Pfizer
PFE
Mkt Cap152.69B
Pfizer develops vaccines and therapeutics for a wide range of diseases, including those in Tonix's research areas, making it a direct competitor.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments and vaccines for infectious diseases, competing with Tonix.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences focuses on antiviral drugs for infectious diseases, directly competing with Tonix's development of treatments for similar conditions.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals is involved in the development of treatments for infectious diseases, making it a competitor to Tonix.
Sanofi
SNY
Mkt Cap104.76B
Sanofi works on vaccines and treatments for infectious diseases, directly competing with Tonix Pharmaceuticals in several areas.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca develops vaccines and treatments for various diseases, including infectious diseases, competing with Tonix's portfolio.

About

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Show more...
CEO
Seth Lederman
Employees
142
Country
United States
ISIN
US8902608392
WKN
000A40VM0

Listings

XNAS
US
TNXP
STU
DE
TPMN.STU
STU
DE
TPM0.STU
MU
DE
TPM0.MU

0 Comments

Share your thoughts

FAQ

What is Tonix Pharmaceuticals stock price today?▼
The current price of TNXP is $12.73 USD — it has increased by +0.55% in the past 24 hours. Watch Tonix Pharmaceuticals stock price performance more closely on the chart.
What is Tonix Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tonix Pharmaceuticals stocks are traded under the ticker TNXP.
Is Tonix Pharmaceuticals stock price growing?▼
TNXP stock has risen by +1.84% compared to the previous week, the month change is a +15.94% rise, over the last year Tonix Pharmaceuticals has showed a -64.69% decrease.
What is Tonix Pharmaceuticals market cap?▼
Today Tonix Pharmaceuticals has the market capitalization of 218.33M
When is the next Tonix Pharmaceuticals earnings date?▼
Tonix Pharmaceuticals is going to release the next earnings report on November 09, 2026.
What were Tonix Pharmaceuticals earnings last quarter?▼
TNXP earnings for the last quarter are -2.44 USD per share, whereas the estimation was -2.64 USD resulting in a +7.66% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tonix Pharmaceuticals revenue for the last year?▼
Tonix Pharmaceuticals revenue for the last year amounts to 13.11M USD.
What is Tonix Pharmaceuticals net income for the last year?▼
TNXP net income for the last year is -124.02M USD.
How many employees does Tonix Pharmaceuticals have?▼
As of August 20, 2026, the company has 142 employees.
In which sector is Tonix Pharmaceuticals located?▼
Tonix Pharmaceuticals operates in the Health & Wellness sector.
When did Tonix Pharmaceuticals complete a stock split?▼
The last stock split for Tonix Pharmaceuticals was on February 05, 2025 with a ratio of 1:100.
Where is Tonix Pharmaceuticals headquartered?▼
Tonix Pharmaceuticals is headquartered in BERKELEY HEIGHTS, United States.